Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325366 | 0.83 | ITGB3 (0.50) | ITGB3ITGAVMIFCA2ALDH1A1 | |
| SCHEMBL6251346 | 0.78 | MIF (0.35) | ESR2ESR1MIFGRM2GRM5 | |
| SCHEMBL16084399 | 0.67 | — | — | |
| SCHEMBL10924973 | 0.67 | — | — | |
| SCHEMBL27720009 | 0.67 | KMT2A (0.40) | ALDH1A1 | |
| SCHEMBL24060778 | 0.66 | OPRM1 (0.37) | OPRM1ESR2ESR1MMP2MMP9 | |
| SCHEMBL12511520 | 0.65 | OPRM1 (0.46) | OPRM1 | |
| SCHEMBL6319856 | 0.64 | ITGB3 (0.42) | ITGB3ITGAVESR2ESR1MIF | |
| SCHEMBL6326443 | 0.64 | ITGB3 (0.42) | ITGB3ITGAVESR2ESR1MIF | |
| SCHEMBL6321357 | 0.64 | ITGB3 (0.42) | ITGB3ITGAVESR2ESR1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGB3 3/4885ITGAV 6/4885OPRM1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.